Today, Michel Bouvier, the IRIC’s CEO, and his team, publish an article in Nature Communications.
In other words, Professor Bouvier’s team identified the specific domains within the receptor that are responsible for activating specific signalling pathways, which explains how different drugs binding to the b2-adrenergic receptor can activate distinct signalling pathways.
The discovery opens the path for the rational design of drugs that selectively activate signalling pathways of therapeutic importance while avoiding those involved in undesirable side effects.
Michel Bouvier is internationally recognized for his expertise and discoveries on GPCRs.
To read the full article: http://www.nature.com/articles/s41467-017-02257-x
Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity